Multifaceted p21 in carcinogenesis,stemness of tumor and tumor therapy

• 作者: Bo-Duan Xiao Fang Huang Jiong Wu Xiao-Yuan Jia Yi-Gang Wang Yu-Jia Zhao
• 来源期刊: 世界干细胞杂志:英文版(电子版)
• 学科: 医学
• 关键词: P21 CDKN1A TUMORIGENESIS Circular RNA Stemness of tumor Cancer stem cells Tumor therapy
• 年，卷（期）: 2020,（6）
• 页码范围: 481-487
• 页数: 7页
• 分类号: R73

摘要

Cancer cells possess metabolic properties that are different from those of benign cells.p21,encoded by CDKN1A gene,also named p21Cip1/WAF1,was first identified as a cyclin-dependent kinase regulator that suppresses cell cycle G1/S phase and retinoblastoma protein phosphorylation.CDKN1A(p21)acts as the downstream target gene of TP53(p53),and its expression is induced by wild-type p53 and it is not associated with mutant p53.p21 has been characterized as a vital regulator that involves multiple cell functions,including G1/S cell cycle progression,cell growth,DNA damage,and cell stemness.In 1994,p21 was found as a tumor suppressor in brain,lung and colon cancer by targeting p53 and was associated with tumorigenesis and metastasis.Notably,p21 plays a significant role in tumor development through p53-dependent and p53-independent pathways.In addition,expression of p21 is closely related to the resting state or terminal differentiation of cells.p21 is also associated with cancer stem cells and acts as a biomarker for such cells.In cancer therapy,given the importance of p21 in regulating the G1/S and G2 check points,it is not surprising that p21 is implicated in response to many cancer treatments and p21 promotes the effect of oncolytic virotherapy.